<div id="readability-page-1"><div><p>Ono Pharmaceutical Co., Ltd. announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. Summary of Data and Findings from the 2-year results of the MOTION Phase 3 Study Methods: The global Phase 3 MOTION study (NCT05059262) aims to evaluate the efficacy and safety of vimseltinib for the treatment of TGCT in cases where surgical remove of the tumor is not an options. The study consists of two parts.</p><p>In Part 1, eligible study participants were assigned to receive either vimseltinib or matching placebo for 24 weeks. Participants assigned to placebo in Part 1 had the option to receive vimseltinib for Part 2. Part 2 was a long-term treatment phase in which all participants received open-label vimseltinib. Patients received vimseltinib 30 mg twice weekly in all periods.</p><p>Objective response rate (ORR) based on best overall response was assessed by independent radiological review (IRR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and per Tumor Volume Score (TVS). Duration of response (DOR) and safety were also evaluated.</p></div></div>

小野制藥(ADR)

<p>小野製藥 (ADR) 將在 2025 年歐洲醫學腫瘤學會大會上展示其 MOTION III 期研究中 vimseltinib 治療腱鞘鉅細胞瘤（TGCT）兩年的療效和安全性結果。該研究評估了 vimseltinib 在無法進行手術切除的患者中的有效性，參與者在兩部分研究中接受藥物或安慰劑。結果包括基於獨立評審的客觀反應率和安全性評估</p>

Ono Pharmaceutical Co., Ltd. Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study ofromVIMZA in Patients with Tenosynovial Giant Cell Tumor at the European Society for Medical Oncology Congress 2025

小野製藥有限公司在 2025 年歐洲腫瘤醫學學會大會上公佈了 VIMZA 用於腱鞘鉅細胞瘤患者的 MOTION 三期研究的兩年療效和安全性結果